Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit

Neurocritical Care

Volumn 11, Issue 1, 2009, Pages 14-19

  Murphy, Theresa ^a   Dhar, Rajat ^b   Diringer, Michael ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Conivaptan; Hyponatremia; Inappropriate ADH syndrome; SIADH; Sodium; Vasopressin receptors

Indexed keywords

CONIVAPTAN; SODIUM; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPONATREMIA; HYPOTENSION; INTENSIVE CARE UNIT; MALE; PHLEBITIS; PRIORITY JOURNAL; RELATIVE DENSITY; TREATMENT RESPONSE; URINE VOLUME; BLOOD; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG PULSE THERAPY; INTENSIVE CARE; METHODOLOGY; RETROSPECTIVE STUDY; SCHWARTZ BARTTER SYNDROME; URINE;

BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; INTENSIVE CARE; PULSE THERAPY, DRUG; RECEPTORS, VASOPRESSIN; RETROSPECTIVE STUDIES; SODIUM; SPECIFIC GRAVITY; URINE;

EID: 70349327412     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-008-9179-3     Document Type: Article

References (25)

1. MC Lester PB Nelson 1981 Neurological aspects of vasopressin release and the syndrome of inappropriate secretion of antidiuretic hormone Neurosurgery 8 6 735 740 10.1097/00006123-198106000-00020 7279164 10.1097/00006123-198106000- 00020 1:STN:280:DyaL38%2Fhtl2ltw%3D%3D
2. T Doczi J Tarjanyi E Huszka J Kiss 1982 Syndrome of inappropriate secretion of antidiuretic hormone after head injury Neurosurgery 10 6 Pt 1 685 688 7110540 1:STN:280:DyaL383nt1ygtw%3D%3D
3. AI Qureshi MF Suri GY Sung, et al. 2002 Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage Neurosurgery 50 4 749 755 10.1097/00006123-200204000-00012 11904025 10.1097/00006123-200204000-00012 (Pubitemid 36322799)
4. AA Rabinstein EF Wijdicks 2003 Hyponatremia in critically ill neurological patients Neurologist 9 6 290 300 10.1097/01.nrl.0000095258.07720.89 14629783 10.1097/01.nrl.0000095258.07720.89 (Pubitemid 37484848)
5. AS Multz 2007 Vasopressin dysregulation and hyponatremia in hospitalized patients J Intensive Care Med 22 4 216 223 10.1177/0885066607301360 17712057 10.1177/0885066607301360 (Pubitemid 47094109)
6. H Pasantes-Morales RA Lezama G Ramos-Mandujano KL Tuz 2006 Mechanisms of cell volume regulation in hypo-osmolality Am J Med 119 Suppl 1(7) S4 S11 10.1016/j.amjmed.2006.05.002 16843084 10.1016/j.amjmed.2006.05.002 1:CAS:528:DC%2BD28XnslWjtLY%3D
7. SR Gullans JG Verbalis 1993 Control of brain volume during hyperosmolar and hypoosmolar conditions Annu Rev Med 44 289 301 10.1146/annurev.me.44.020193. 001445 8476251 10.1146/annurev.me.44.020193.001445 1:STN:280: DyaK3s3js1elsQ%3D%3D
8. A Bhardwaj 2006 Neurological impact of vasopressin dysregulation and hyponatremia Ann Neurol 59 2 229 236 10.1002/ana.20788 16437573 10.1002/ana.20788 1:CAS:528:DC%2BD28XhvVSlu7s%3D (Pubitemid 43202475)
9. CL Fraser AI Arieff 1997 Epidemiology, pathophysiology, and management of hyponatremic encephalopathy Am J Med 102 1 67 77 10.1016/S0002-9343(96)00274-4 9209203 10.1016/S0002-9343(96)00274-4 1:CAS:528:DyaK2sXhtlelsL8%3D (Pubitemid 27089989)
10. MN Diringer AR Zazulia 2006 Hyponatremia in neurologic patients: consequences and approaches to treatment Neurologist 12 3 117 126 10.1097/01.nrl.0000215741.01699.77 16688013 10.1097/01.nrl.0000215741.01699.77 (Pubitemid 43756309)
11. SC Singhi PD Singhi B Srinivas, et al. 1995 Fluid restriction does not improve the outcome of acute meningitis Pediatr Infect Dis J 14 6 495 503 10.1097/00006454-199506000-00006 7667054 1:STN:280:DyaK2Mzps1Ggsw%3D%3D
12. EF Wijdicks M Vermeulen A Hijdra J van Gijn 1985 Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol 17 2 137 140 10.1002/ana.410170206 3977297 10.1002/ana.410170206 1:STN:280:DyaL2M7kslGqtw%3D%3D (Pubitemid 15170433)
13. P Gross D Reimann J Henschkowski M Damian 2001 Treatment of severe hyponatremia: conventional and novel aspects J Am Soc Nephrol 12 Suppl 17 S10 S14 11251026 1:CAS:528:DC%2BD3MXhtlKisr0%3D
14. HK Mohmand D Issa Z Ahmad JD Cappuccio RW Kouides RH Sterns 2007 Hypertonic saline for hyponatremia: risk of inadvertent overcorrection Clin J Am Soc Nephrol 2 6 1110 1117 10.2215/CJN.00910207 17913972 10.2215/CJN.00910207
15. MH Woo PB Kale-Pradhan 1997 Fludrocortisone in the treatment of subarachnoid hemorrhage-induced hyponatremia Ann Pharmacother 31 5 637 639 9161663 1:CAS:528:DyaK2sXjsV2nsbc%3D
16. EF Wijdicks M Vermeulen P van Brummelen J van Gijn 1988 The effect of fludrocortisone acetate on plasma volume and natriuresis in patients with aneurysmal subarachnoid hemorrhage Clin Neurol Neurosurg 90 3 209 214 10.1016/0303-8467(88)90023-6 3197346 10.1016/0303-8467(88)90023-6 1:STN:280:DyaL1M%2FmtlOrtw%3D%3D (Pubitemid 18249751)
17. P Porzio M Halberthal D Bohn ML Halperin 2000 Treatment of acute hyponatremia: ensuring the excretion of a predictable amount of electrolyte-free water Crit Care Med 28 6 1905 1910 10.1097/00003246-200006000-00037 10890640 10.1097/00003246-200006000-00037 1:STN:280:DC%2BD3czks1Kqtg%3D%3D
18. MJ Cawley 2007 Hyponatremia: current treatment strategies and the role of vasopressin antagonists Ann Pharmacother 41 5 840 850 10.1345/aph.1H502 17405824 10.1345/aph.1H502 1:CAS:528:DC%2BD2sXlvFyrsbs%3D (Pubitemid 46752663)
19. RM Hays 2006 Vasopressin antagonists - progress and promise N Engl J Med 355 20 2146 2148 10.1056/NEJMe068236 17105758 10.1056/NEJMe068236 1:CAS:528:DC%2BD28Xht1Wksb7O (Pubitemid 44749324)
20. C Palm F Pistrosch K Herbrig P Gross 2006 Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia Am J Med 119 Suppl 1(7) S87 S92 10.1016/j.amjmed.2006.05.014 16843091 10.1016/j.amjmed.2006.05.014 1:CAS:528:DC%2BD28XnslWjurs%3D
21. AA Rabinstein 2006 Vasopressin antagonism: potential impact on neurologic disease Clin Neuropharmacol 29 2 87 93 10.1097/00002826-200603000-00006 16614541 10.1097/00002826-200603000-00006 1:CAS:528:DC%2BD28XjsVersr8%3D (Pubitemid 44357158)
22. D Zeltser S Rosansky H van Rensburg JG Verbalis N Smith 2007 Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia Am J Nephrol 27 5 447 457 10.1159/000106456 17664863 10.1159/000106456 1:CAS:528:DC%2BD2sXhtVOrtbzO (Pubitemid 47482001)
23. JK Ghali MJ Koren JR Taylor, et al. 2006 Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia J Clin Endocrinol Metab 91 6 2145 2152 10.1210/jc.2005-2287 16522696 10.1210/jc.2005-2287 1:CAS:528:DC%2BD28XlvVCgsL8%3D (Pubitemid 43854997)
24. Vaprisol (conivaptan hydrochloride injection). Prescribing information. Deerfield Ill: Astellas Pharma US, Inc.; 2007.
25. M Burnier AF Fricker D Hayoz J Nussberger HR Brunner 1999 Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects Eur J Clin Pharmacol 55 9 633 637 10.1007/s002280050685 10638391 10.1007/s002280050685 1:CAS:528: DyaK1MXntl2qs7g%3D